Kala Pharmaceuticals, Inc. (KALA)

Kala Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the development and commercialization of therapies for eye diseases. Founded in 2009, the company has used its proprietary AMPPLIFY mucus-penetrating particle drug delivery technology to improve the treatment of ocular diseases. Kala is headquartered in Watertown, Massachusetts. As of the latest available information, the company is led by CEO Mark Iwicki. Kala Pharmaceuticals has been committed to addressing unmet medical needs in ophthalmology and had ventured into products like INVELTYS®, the first and only twice-daily ocular corticosteroid for post-operative inflammation and pain following ocular surgery. For individuals interested in the company's financial standing, looking up the most recent earnings reports and press releases will provide insights into its revenue trends and growth trajectory.